{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:23:46Z","timestamp":1790342626530,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","award":["Amicus Therapeutics"],"award-info":[{"award-number":["Amicus Therapeutics"]}],"id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fabry disease (FD) is a rare inherited X-linked lysosomal disorder caused by the deficiency or dysfunction of the enzyme \u03b1-galactosidase. This leads to a detrimental accumulation of globotriaosylceramide (Gb3) within multiple cell types. Enzyme replacement therapies (ERTs), including agalsidase alfa and agalsidase beta, can diminish Gb3 levels. Published real-world data on the time, cost and burden associated with the administration of ERTs are limited. These evidence gaps were addressed by generating real-world data quantifying the burden of agalsidase alfa and beta infusions for FD treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>The study (ClinicalTrials.gov number: NCT04281537) comprised a prospective time-and-motion and a cross-sectional evaluation of self-reported burden and outcomes associated with ERT administration (including work productivity and out-of-pocket costs) from multiple perspectives (healthcare professionals [HCPs], patients, and caregivers). To assess patient\/caregiver experience and burden of ERT, the primary objective was to quantify the total time spent by HCPs in the preparation and administration of a single dose of ERT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 76 patients and 6 caregivers were included. Of the 76 patients, (Brazil [<jats:italic>n<\/jats:italic>\u2009=\u200923], Japan [<jats:italic>n<\/jats:italic>\u2009=\u20094], Taiwan [<jats:italic>n<\/jats:italic>\u2009=\u200930] and Turkey [<jats:italic>n<\/jats:italic>\u2009=\u200919]), 41% were female and the mean (standard deviation [SD]) age at diagnosis was 41.1 (17.1) years. Overall, most patients (70%, <jats:italic>n<\/jats:italic>\u2009=\u200953) had moderate FD and were treated with agalsidase beta (65%, <jats:italic>n<\/jats:italic>\u2009=\u200948); this was the predominant ERT administered in Brazil (100%, <jats:italic>n<\/jats:italic>\u2009=\u200923) and Turkey (74%, <jats:italic>n<\/jats:italic>\u2009=\u200914); most patients in Japan (75%, <jats:italic>n<\/jats:italic>\u2009=\u20093) and Taiwan (67%, <jats:italic>n<\/jats:italic>\u2009=\u200920) received agalsidase alfa. The mean (SD) HCP time spent on all ERT activities was 151.9 (62.5) minutes (2.5 [1.0] hours); the mean (SD) time spent on pre- and post-infusion activities was 20.9 (13.4) (0.3 [0.2] hours) and 12.8 (9.6) minutes (0.2 [0.2] hours), respectively. The mean (SD) time spent by patients for all ERT activities was 368.5 (191.5) minutes (6.1 [3.2] hours); 21% (<jats:italic>n<\/jats:italic>\u2009=\u200916\/76) of patients and 50% (<jats:italic>n<\/jats:italic>\u2009=\u20093\/6) of carers took time off work for an ERT episode.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The multi-region findings provide a more complete picture of the burden associated with ERT administration for FD treatment on patients, caregivers, and HCPs. Results may support further cost-effectiveness modelling for novel treatment approaches and inform treatment decisions and patient management.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03707-2","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:39:07Z","timestamp":1754919547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta"],"prefix":"10.1186","volume":"20","author":[{"given":"Ian","family":"Keyzor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema Kalkan","family":"U\u00e7ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"T\u00fcmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Baldock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Shohet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"4","key":"3707_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","volume":"60","author":"M Gilchrist","year":"2023","unstructured":"Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, et al. Prevalence of Fabry disease-causing variants in the UK biobank. J Med Genet. 2023;60(4):391\u20136.","journal-title":"J Med Genet"},{"issue":"2","key":"3707_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns9020031","volume":"9","author":"V Gragnaniello","year":"2023","unstructured":"Gragnaniello V, Burlina AP, Commone A, Gueraldi D, Puma A, Porc\u00f9 E, et al. Newborn screening for Fabry disease: current status of knowledge. Int J Neonatal Screen. 2023;9(2):31.","journal-title":"Int J Neonatal Screen"},{"issue":"11","key":"3707_CR3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750\u201360.","journal-title":"J Med Genet"},{"issue":"11","key":"3707_CR4","first-page":"790","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet Med Off J Am Coll Med Genet. 2009;11(11):790\u20136.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"issue":"5","key":"3707_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, et al. Agalsidase Alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351\u20138.","journal-title":"J Med Genet"},{"key":"3707_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"3707_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","volume":"10","author":"M Arends","year":"2015","unstructured":"Arends M, Hollak CEM, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015;10:77.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3707_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, K\u00f6rver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41(1):141\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"3707_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77\u201386.","journal-title":"Ann Intern Med"},{"issue":"4 Suppl","key":"3707_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1590\/S1415-47572012000600009","volume":"35","author":"T Alegra","year":"2012","unstructured":"Alegra T, Vairo F, de Souza MV, Krug BC, Schwartz IVD. Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis. Genet Mol Biol. 2012;35(4 Suppl):947\u201354.","journal-title":"Genet Mol Biol"},{"key":"3707_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MGW, Hollak CEM. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3707_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353\u20138.","journal-title":"J Med Genet"},{"issue":"5","key":"3707_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/21678707.2018.1469978","volume":"6","author":"G Sunder-Plassmann","year":"2018","unstructured":"Sunder-Plassmann G, Schiffmann R, Nicholls K. Migalastat for the treatment of Fabry disease. Expert Opin Orphan Drugs. 2018;6(5):301\u20139.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"5","key":"3707_CR14","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3390\/ijms24054548","volume":"24","author":"I Iacobucci","year":"2023","unstructured":"Iacobucci I, Hay Mele B, Cozzolino F, Monaco V, Cimmaruta C, Monti M, et al. Enzyme replacement therapy for FABRY disease: possible strategies to improve its efficacy. Int J Mol Sci. 2023;24(5):4548.","journal-title":"Int J Mol Sci"},{"key":"3707_CR15","unstructured":"Fabrazyme INN-agalsidase. beta: Summary of Product Characteristics [Internet]. European Medicines Agency (EMA); Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fabrazyme-epar-product-information_en.pdf"},{"key":"3707_CR16","unstructured":"Replagal INN-agalsidase. alfa: Summary of Product Characteristics [Internet]. European Medicines Agency (EMA); Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en.pdf"},{"issue":"22","key":"3707_CR17","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.12968\/bjon.2007.16.22.27768","volume":"16","author":"DA Hughes","year":"2007","unstructured":"Hughes DA, Mlilligan A, Mehta A. Home therapy for lysosomal storage disorders. Br J Nurs Mark Allen Publ. 2007;16(22):1384.","journal-title":"Br J Nurs Mark Allen Publ"},{"issue":"10","key":"3707_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.12968\/bjon.2008.17.10.29481","volume":"17","author":"A Cousins","year":"2008","unstructured":"Cousins A, Lee P, Rorman D, Raas-Rothschild A, Banikazemi M, Waldek S, et al. Home-based infusion therapy for patients with Fabry disease. Br J Nurs Mark Allen Publ. 2008;17(10):653\u20137.","journal-title":"Br J Nurs Mark Allen Publ"},{"issue":"6","key":"3707_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","volume":"15","author":"A Milligan","year":"2006","unstructured":"Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs Mark Allen Publ. 2006;15(6):330\u20133.","journal-title":"Br J Nurs Mark Allen Publ"},{"key":"3707_CR20","first-page":"85","volume":"12","author":"D Concolino","year":"2017","unstructured":"Concolino D, Amico L, Cappellini MD, Cassinerio E, Conti M, Donati MA, et al. Home infusion program with enzyme replacement therapy for Fabry disease: the experience of a large Italian collaborative group. Mol Genet Metab Rep. 2017;12:85\u201391.","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"3707_CR21","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1016\/j.ymgme.2021.11.343","volume":"135","author":"H Yamakawa","year":"2022","unstructured":"Yamakawa H, Kosuga M, Hoshino Y, Kaku I, Harada H, Koga A, et al. The need for home enzyme replacement therapy for patients with lysosomal disease in Japan. Mol Genet Metab. 2022;135(2):S128\u20139.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"3707_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353\u201365.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"3707_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13023-023-02775-6","volume":"18","author":"M G\u00fcnd\u00fcz","year":"2023","unstructured":"G\u00fcnd\u00fcz M, Y\u00fcksel G\u00fcdek Y, Kasapkara \u00c7S. Out-of-pocket health expenditures in patients living with Inborn errors of metabolism. Orphanet J Rare Dis. 2023;18(1):179.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3707_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12876-023-02726-2","volume":"23","author":"EB Tapper","year":"2023","unstructured":"Tapper EB, Krieger N, Przybysz R, Way N, Cai J, Zappe D, et al. The burden of nonalcoholic steatohepatitis (NASH) in the united States. BMC Gastroenterol. 2023;23(1):109.","journal-title":"BMC Gastroenterol"},{"key":"3707_CR25","doi-asserted-by":"crossref","unstructured":"Allen-Ramey FC, Gupta S, DiBonaventura M, daCosta. Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes. Int J Chron Obstruct Pulmon Dis. 2012;7:779\u201387.","DOI":"10.2147\/COPD.S35501"},{"key":"3707_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s13023-022-02523-2","volume":"17","author":"C Li","year":"2022","unstructured":"Li C, Xu H, Gong L, Wang A, Dong X, Yuan K, et al. Work productivity and activity in patients with SAPHO syndrome: a cross-sectional observational study. Orphanet J Rare Dis. 2022;17:381.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3707_CR27","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/hae.14731","volume":"29","author":"T Burke","year":"2023","unstructured":"Burke T, Rodriguez-Santana I, Chowdary P, Curtis R, Khair K, Laffan M, et al. Humanistic burden of problem joints for children and adults with haemophilia. Haemophilia. 2023;29(2):608\u201318.","journal-title":"Haemophilia"},{"issue":"2","key":"3707_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/ecco-jcc\/jjaa159","volume":"15","author":"S Ghosh","year":"2020","unstructured":"Ghosh S, Sensky T, Casellas F, Rioux LC, Ahmad T, M\u00e1rquez JR, et al. A global, prospective, observational study measuring disease burden and suffering in patients with ulcerative colitis using the pictorial representation of illness and Self-Measure tool. J Crohns Colitis. 2020;15(2):228\u201337.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"3707_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/00019053-200927050-00002","volume":"27","author":"AB Schultz","year":"2009","unstructured":"Schultz AB, Chen CY, Edington DW. The cost and impact of health conditions on presenteeism to employers: a review of the literature. PharmacoEconomics. 2009;27(5):365\u201378.","journal-title":"PharmacoEconomics"},{"issue":"3","key":"3707_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","volume":"67","author":"J McCambridge","year":"2014","unstructured":"McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67(3):267\u201377.","journal-title":"J Clin Epidemiol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03707-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03707-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03707-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:41:59Z","timestamp":1757374919000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03707-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3707"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03707-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was designed and monitored in accordance with the ethical principles of Good Clinical Practice guidelines and the Declaration of Helsinki. The clinical study protocol was reviewed and approved by the appropriate independent ethics committee or institutional review board at each study site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IK: was an employee of Amicus Therapeutics, Ltd. at the time of the study and holds stocks and shares in Amicus Therapeutics, Inc. JDG: Is an employee of Amicus Therapeutics, Inc. and holds stocks and shares in Amicus Therapeutics, Inc. SS: Is an employee of Amicus Therapeutics, Ltd. and holds stocks and shares in Amicus Therapeutics, Inc. LB: Employee of OPEN Health at the time of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"419"}}